DEA Law Safety Therapy 
Veriheal
FEBRUARY 23, 2024
As the Drug Enforcement Administration (DEA) and federal government draw closer to moving cannabis from a Schedule I to a Schedule III substance , more groups have begun to put their weight behind the movement. Countless veterans suffer from these ailments, and, as such, are pushing for access to as many treatments and therapies as possible.
Cannabis Law Report
DECEMBER 7, 2021
On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
FEBRUARY 1, 2021
The filing is backed by MAPS (Multidisciplinary Association for Psychedelic Studies) and calls on the DEA to answer a four-year-old filing requesting approval of his application to become a federally registered marijuana cultivator. Back in 2016, the DEA said they were starting the process of approving “additional marijuana cultivators.”
Cannabis Law Report
JULY 9, 2021
The state of the law on psychedelic substances is in flux. The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.” Psychedelic therapy is not a fringe phenomenon. Some of the most promising substances, and the law applicable to each, are outlined below: Psilocybin.
Canna Law Blog
NOVEMBER 6, 2021
But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Research was permitted in the mid-20th century, until the law stepped in. Psilocybin, a compound produced by many species of fungi, is one of the most well-studied psychedelics.
Cannabis Law Report
JULY 1, 2021
From their blog… Q&A with Mason Marks on New Psychedelics Law and Regulation Initiative. On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation.
Cannabis Law Report
NOVEMBER 22, 2019
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . Most recently the FDA awarded MMJ International Holdings ? .
Expert insights. Personalized for you.
99 
Let's personalize your content